Background Early acute kidney injury (AKI) diagnosis is needed to pursue treatment trials. We evaluated cystatin C (CysC) as an early biomarker of serum creatinine (SCr)-AKI and an alternative to define AKI. Methods We studied 160 non-cardiac children in the intensive care unit (ICU). We measured daily CysC and SCr. AKI was staged by KDIGO (Kidney Disease: Improving Global Outcomes) guidelines using SCr and CysC (CysC-AKI). We calculated area under the curve (AUC) for (1) neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1) and urine CysC to diagnose SCr-and CysC-AKI; and (2) for CysC to diagnose SCr-AKI. We evaluated AKI associations with length of stay and ventilation duration. Results We found that 44 % of patients developed SCr-AKI; 32 % developed CysC-AKI. Early ICU NGAL was most diagnostic of CysC-AKI (AUC 0.69, 95% CI 0.54-0.84); IL-18 was most diagnostic for SCr-AKI (AUC 0.69 95% CI 0.55-0.82). Combining SCr and CysC-AKI definition led to higher biomarker diagnostic AUC's. CysC-AKI was not more strongly associated with clinical outcomes. Early ICU CysC predicted SCr-AKI development (AUC 0.70, 95 % CI 0.53-0.89). Conclusions Our findings do not support replacing SCr by CysC to define AKI. Early ICU CysC predicts SCr-AKI development and combined SCr-CysC-AKI definition leads to stronger AKI biomarker associations.
Introduction
Acute kidney injury (AKI) is a frequent condition associated with poor outcome in children admitted to the pediatric intensive care unit (PICU). Therapeutic interventions have failed to reduce AKI morbidity and mortality. Progress has been impaired by reliance on a delayed AKI biomarker, serum creatinine (SCr) [1] . Human studies have been performed in an attempt to validate novel biomarkers of early AKI diagnosis identified in animal models [2] [3] [4] [5] [6] [7] [8] . Although these initial studies were encouraging, recent publications have revealed only fair to good diagnostic accuracy of new AKI biomarkers [2, 7, [9] [10] [11] .
A possible reason for the lack of successful early urinary AKI biomarkers is that the "gold standard" used for AKI diagnosis is a rise in SCr, as applied in the Risk, Injury, Failure, End-Stage Renal Disease (RIFLE) [12] , Acute Kidney Injury Network (AKIN) [13] and the Kidney Disease: Improving Global Outcomes (KDIGO) definitions for AKI [14] . SCr concentrations vary with age, gender, muscle mass, medication, and intravascular volume status [15] . Furthermore, renal reserve must be overcome before any change in SCr will occur after injury. This likely leads to misclassification of AKI status and inadequate estimation of the performance of new AKI diagnostic biomarkers.
Serum cystatin C (CysC), a low molecular weight protein measurable in blood and freely filtered by the glomerulus, is purported to be less affected by age and gender [16] . In children with chronic kidney disease, CysC is a more accurate marker of the glomerular filtration rate (GFR) [17, 18] . Acute CysC changes may therefore provide more accurate determinations of acute functional changes in kidney filtration. Some studies have suggested that serum CysC concentration increases with AKI occur before a rise in SCr, leading to the hypothesis that CysC may serve as an "early AKI biomarker" [7, 19] . However, malignancy, corticosteroids, and thyroid dysfunction may lead to variability in serum CysC [20] [21] [22] [23] .
We sought to evaluate the use of CysC in children admitted to the PICU as: (1) an alternative to SCr for defining AKI; and (2) an early biomarker of SCr-defined AKI. We hypothesized that if CysC is a more accurate marker of acute changes in GFR than SCr is, then clinical outcomes and urine injury biomarkers should be more strongly associated with CysCdefined AKI than with SCr-defined AKI.
Materials and methods

Design, setting, and subject recruitment
This was a prospective cohort study performed in children between 1 month and 18 years old admitted to the Montreal Children's Hospital (MCH) PICU, Canada between November 2007 and September 2010. Children between 1 month and 18 years old admitted to the PICU were eligible. We focused on children who were not immediately post-operative from cardiac surgery. Exclusion criteria were: known end-stage renal disease, having received a renal transplant, a high likelihood of death in the following 48 h (determined by the PICU attending staff) and presence of <25 % of PICU days with both a CysC and a SCr value available (determined by dividing number of available daily values by PICU admission days). Research ethics board approval was obtained (Montreal Children's Hospital) before initiating study activities, which adhered to the Declaration of Helsinki. Parents provided informed consent before enrolment.
Overall study procedure
In subjects recruited within the first 48 h of PICU admission, daily clinical data, urine (up to 30 cc, freshly voided from a urinary catheter or from diapers using cotton balls, at approximately 8:00 am) and blood were collected for up to 14 days of PICU admission. Blood was collected during routine morning PICU blood collection, with extraction of an additional 1 to 2 cc of blood for this study. If blood work was not planned by the PICU team, no blood was obtained. The MCH biochemistry laboratory stores serum from all routine blood draws for 2 weeks at -20°C. We obtained this serum for SCr and CysC measurements from the days before recruitment (e.g., PICU day 1, if recruited PICU day 2). In subjects recruited after 48 h of PICU admission, the protocol only included blood collection for CysC and SCr measurement (not urine for biomarkers). All biospecimens were centrifuged at 1,000 g for 15 min at room temperature. Urine and serum were aliquoted and stored at -80°C until biomarker measurement, performed every 2 to 5 months.
Clinical data collection
The following clinical variables were collected: age, gender, primary PICU diagnosis, variables required for the Pediatric Risk of Mortality (PRISM) score [24] and Pediatric Logistic Organ Dysfunction (PELOD) score [25] , requirement of mechanical ventilation, urinary catheter, vasopressors or renal replacement therapy, and treatment with steroids or thyroid medications. The following clinical outcomes were collected: duration of PICU and hospital stay, duration of mechanical ventilation and mortality. Baseline estimated GFR was calculated by the Schwartz formula [26] using the lowest SCr in the 3 months before PICU admission ("baseline" SCr). When no baseline SCr was available, a normal baseline estimated GFR of 120 ml/min/1.73 m 2 was assumed (due to the extremely low prevalence of chronic kidney disease in children [27] ).
Laboratory measurements
SCr was measured at our central biochemistry laboratory using an IDMS-traceable assay. Urine neutrophil gelatinaseassociated lipocalin (NGAL) and interleukin-18 (IL-18), and serum CysC were measured at the Cincinnati Children's Hospital Medical Center Biomarker Laboratory, Ohio (PD, MB, QM) [7, 28] and kidney injury molecule-1 (KIM-1) was measured at Brigham & Women's Hospital, Harvard, Massachusetts (JV, VS) [29] . NGAL was measured using a commercial ELISA kit (Bioporto, Gentofte, Denmark) per the manufacturer's instructions. The average intra-assay and inter-assay coefficient of variations (CV, verified) was between 2.5 and 6.3 %. IL-18 was measured in the same laboratory using an IL-18 ELISA kit (Medical & Biological Laboratories, Nagoya, Japan) per the manufacturer's instructions. The verified inter-and intra-assay CVs ranged between 3.01 % and 10 %. KIM-1 was measured using a microbeadbased assay on a Luminex system [29] . Inter-and intra-assay CVs were <15 %. CysC was measured using a nephelometer (Siemens BN-II, Siemens, AG; www.Siemens.com) (company-reported CVs <1.1 %). Individuals performing biomarker measurements were blinded to clinical data. 
CysC-based AKI definitions
We defined AKI according to change in CysC (hereafter CysC-AKI). We applied the KDIGO definition in a similar way to KDIGO-SCr criteria, to the extent that this was feasible (including the timing of rise criterion, the eGFR criterion of stage 3, but excluding the equivalent of "0.3 mg/dl rise from baseline" of the stage 1 SCr criterion). It was necessary to determine a reasonable way to estimate baseline (pre-PICU) CysC which could be easily reproducible in other studies and in clinical care, when pre-PICU baseline CysC would not be available. We used the Schwartz formula-estimated baseline eGFR to back-calculate baseline CysC concentrations using a validated CysC GFR formula [18, 26] .
Combined SCr and CysC AKI definition
We additionally classified patients as having attained both SCr-and Cys-AKI status during PICU admission (referred to as SCr+CysC-AKI).
Statistical analysis
The level of agreement between different AKI definitions using SCr and CysC was evaluated using the kappa statistic.
CysC as an alternative method to define AKI
Associations between urine AKI biomarkers and SCr-AKI, CysC-AKI, and SCr+CysC-AKI definitions Subjects with urine available were included in these analyses. As a crude method to evaluate the relationship between SCrand CysC-AKI and urine AKI biomarkers, peak PICU biomarker concentrations were compared across SCr and CysC-AKI severity strata using Kruskal-Wallis tests. AKI was defined by four categories: (1) no SCr and no CysC-AKI, (2) SCr-AKI only, (3) CysC-AKI only, and (4) SCr and CysC-AKI. Peak urine biomarker concentrations were compared between the categories. Receiver operating characteristic (ROC) curves with calculation of area under the curve (AUC) were used to evaluate biomarkers for AKI diagnosis (using SCr-AKI, CysC-AKI, and SCr+CysC-AKI definitions) when obtained on: (1) the day of AKI attainment (discrimination), and (2) in the first 48 h of PICU (early PICU AKI diagnosis).
Comparing associations between SCr-AKI versus CysC-AKI and outcomes
All subjects were included. Multivariate Cox proportional hazards regression was used to evaluate and compare whether SCr-AKI and CysC-AKI were associated with increased risk for longer length of PICU stay (LOS) and for mechanical ventilation (LOV). Age, gender, PRISM, trauma and neurological primary diagnosis, presence/absence of infection (respiratory and non-respiratory), and vasopressor requirement were controlled for. Unadjusted and adjusted hazard ratios (HR) (and 95 % confidence intervals) were calculated, with a HR<1 indicating AKI as a risk factor for longer length of stay or ventilation (i.e., AKI reduces the "risk" of discharge or extubation). We performed similar analyses with the SCr+ CysC-AKI definition.
CysC as an early biomarker of SCr-AKI
All subjects were included. The day of SCr-AKI attainment was identified. The AUC for CysC drawn 2 days before, 1 day before, and on the day of first SCr-AKI attainment were calculated to diagnose the presence of AKI. The first PICU CysC concentrations (if drawn within 48 h of PICU admission) were used to calculate AUC for future AKI development in children who did not yet have AKI at PICU admission. As a secondary analysis, the continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI) of early PICU CysC were calculated to evaluate improvement in predicting AKI development, compared to using a predictive model of age and admission PRISM score alone [30, 31] . Analyses were performed using STATA SE 10® (StataCorp, College Station, TX, USA). Figure 1 describes the study flow. There were 160 subjects available for analysis. Table 1 shows that PELOD score, length of PICU stay and of mechanical ventilation, and proportion receiving vasopressors were significantly higher in AKI versus non-AKI subjects using both definitions. PRISM score, duration of hospital stay, and renal replacement therapy were only significantly higher in subjects with SCr-defined AKI. Only one subject received thyroxin during PICU admission and 77 (48 %) subjects were treated with steroids at some time during admission (47 % of patients with and 49 % of patients without SCr-AKI, p=0.8). Relationship between urine biomarkers and AKI by SCr and CysC
Results
Study population
Worsening SCr-AKI severity was significantly associated with increasing peak urine NGAL, IL-18, and KIM-1 concentrations, whereas CysC-AKI severity was only significantly associated with increasing peak urine NGAL and urine CysC concentrations (Fig. 2) . Subjects who had both SCr-AKI and CysC-AKI had the highest peak urine biomarker concentrations for all biomarkers (versus patients with no AKI, SCr-AKI only, or CysC-AKI only), but this association was only significant with NGAL and urine CysC (Fig. 3) .
Biomarker diagnostic characteristics for SCr and CysC-AKI Whether AKI was defined by SCr or CysC, urine NGAL obtained on the day of AKI diagnosis had similar AUC for discriminating for presence of AKI (AUC=0.68 and 0.70, respectively, Table 3 ). IL-18 diagnostic characteristics were substantially higher using SCr-AKI (AUC=0.68 versus 0.54). The 85 % specificity and sensitivity biomarker concentration cut-offs for AKI diagnosis by SCr and CysC methods were fairly similar (Table 3) . When the outcome was the combined SCr+ CysC-AKI definition, biomarker associations were overall much stronger (higher AUCs) for urine NGAL, IL-18 and urine CysC expressed in mg/ml (detailed in Table 3 ).
SCr and CysC-AKI diagnosis using biomarkers at PICU admission
The best AUC for predicting CysC-AKI development was for early PICU NGAL (AUC=0.69, Table 4 ); early PICU IL-18 had the best AUC for predicting SCr-AKI (AUC =0.69, Table 4 ). Early PICU NGAL and IL-18 AUC's to predict SCr+CysC-AKI were generally higher (as high as 0.76 and 0.74, respectively) compared to predicting SCr-AKI or CysC-AKI (shown in Table 4 ). When the outcome was stage 2 AKI or worse, NGAL and IL-18 AUCs were significantly higher for predicting SCr-AKI compared to other biomarkers (lower half Table 4 , AUC's = 0.76 and 0.69, respectively); NGAL AUC was substantially higher compared to other biomarkers to predict CysC-AKI stage 2 or worse (lower half of Table 4 , AUC=0.78). The event rate of SCr+CysC-AKI stage 2 was not high enough to perform meaningful analyses. CysC as an "early biomarker" of AKI In 35 patients who attained a 50 % rise in SCr and CysC during PICU admission, 11 (31 %) attained 50 % SCr rise before attaining a 50 % CysC rise; five (15 %) attained 50 % CysC rise before a 50 % SCr rise; and 19 (54 %) attained a 50 % rise by both biomarkers on the same PICU day. As shown in Fig. 4 , AUC for SCr-AKI diagnosis by CysC value (concentration) increased progressively the closer the CysC sampling was to the day of SCr-AKI attainment. AUC of CysC was highest and statistically significant when measured on the day of AKI attainment (Fig. 4c) . The best CysC cut-off for SCr-AKI diagnosis, favoring high specificity and likelihood ratio, was 1.3 mg/l, regardless of CysC sampling day SCR serum creatinine, CysC cystatin C, AKI acute kidney injury Fig. 2 Peak pediatric intensive care unit biomarker concentrations by acute kidney injury severity stratum using SCr-AKI and CysC-AKI definitions. a Box plots (middle line is the median; upper and lower box borders are the 75th and 25th percentile values, respectively) of biomarker concentrations for urine neutrophil gelatinase-associated lipocalin, interleukin-18, kidney injury molecule-1 and urine cystatin C across AKI severity strata (no AKI, stage 1 AKI and stages 2 or 3 AKI).
p values are from performance of a non-parametric test for trend across groups. b Identical analyses but with AKI defined by rise in CysC from baseline (CysC-AKI). SC serum creatinine, SCR-AKI acute kidney injury defined by rise in serum creatinine from baseline, NGAL neutrophil gelatinase-associated lipocalin, AKI acute kidney injury, IL-18 interleukin-18, KIM-1 kidney injury molecule-1, CysC cystatin C, CysC-AKI acute kidney injury defined by rise in serum cystatin C from baseline (panels a-c). Figure 4d and e show that CysC measured within the first 48 PICU hours predicted SCr-AKI development with AUC = 0.71 (Fig. 4d ) and predicted stage 2 SCr-AKI development with AUC = 0.80 (Fig. 4e) . The NRI of first 48/h PICU CysC to predict AKI development over a simple clinical model including age and PRISM score was 0.61 (standard error 0.34, p=0.05); IDI was 0.06 (standard error = 0.04, p=0.1).
Discussion
In recent years, CysC has been proposed as an alternative to SCr for estimating GFR. However, SCr continues to be used by most laboratories worldwide, since no studies have really addressed the extent to which incorporating CysC into clinical care will actually lead to a change in management or a change in health care costs. Our study therefore attempted to perform an initial evaluation of the extent to which CysC in the PICU (where AKI is most common in children's hospitals) might potentially serve to indicate acute renal dysfunction. This is one of the first prospective studies evaluating serum CysC for AKI diagnosis in non-cardiac children admitted to the PICU. We evaluated CysC: (1) to define AKI, and (2) as an early diagnostic biomarker of SCr-AKI. Urine biomarkers and morbidity outcomes were not more associated with CysC-AKI. However, CysC predicted AKI development when obtained early in PICU admission. In addition to our results on CysC, this study contributes to the little published data on urine AKI biomarkers in non-cardiac surgery children admitted to the PICU, providing both urine creatinine-adjusted and unadjusted values for comparison with future studies. We and others have shown that serum CysC is a more accurate marker of GFR than SCr is in children with chronic kidney disease [17, 18, 32] . It is therefore reasonable to hypothesize that acute CysC change might more accurately detect acute GFR reduction than SCr does. To evaluate this, it is imperative to define a reasonable baseline CysC. Some proposed methods have included using CysC concentration at least 3 days before SCr-AKI occurs or using lowest CysC concentrations during ICU admission [19, 33] . These methods Fig. 3 Comparison of peak biomarker concentrations across four AKI categories: No AKI, SCr-AKI only, CysC-AKI only, both SCr+CysC AKI. For all four studied biomarkers, biomarker concentrations are compared between four groups: patients with no AKI by SCr or CysC rise; patients who only have acute kidney injury by SCr rise; patients who only have acute kidney injury by CysC rise; patients who have acute kidney injury using both methods. The p values within the graphs are from performance of a non-parametric test for trend across groups. NGAL neutrophil gelatinase-associated lipocalin, AKI acute kidney injury, SCR-AKI acute kidney injury defined by rise in serum creatinine from baseline, CysC-AKI acute kidney injury defined by rise in serum cystatin C from baseline, SCr+CysC-AKI acute kidney injury defined by rise in serum creatinine and cystatin C from baseline, IL-18 interleukin-18, KIM-1 kidney injury molecule-1, CysC cystatin C are rational for retrospective analysis of previously performed studies, where CysC values throughout the study will already be available at the time of analysis; however, in the ICU setting, where AKI timing is unclear and true baseline CysC will most often not be available, defining a baseline is much more challenging. Our baseline CysC method was rational though not ideal. Two studies of adults used admission CysC as baseline [34, 35] . Both studies found that AKI-hospital outcomes associations were not different whether AKI was defined by SCr or CysC. In a multicenter study of children undergoing cardiac surgery, pre-operative CysC was used as baseline [36] . Thus, when the exact timing of potential injury (e.g., cardiac surgery) is known, defining baseline CysC is simple. Although we only had 20 patients to evaluate, our estimated baseline CysC was similar to true pre-ICU concentrations.
Several studies have used CysC rise as a renal outcome [37] [38] [39] . Given the lack of understanding of CysC rise as a valid AKI outcome, it is difficult to interpret these study findings. We attempted to address this issue. First, there was substantial disagreement between SCr-AKI and CysC-AKI diagnosis, suggesting that these two definitions provide distinct information in several patients. We found that CysC was overall not more strongly associated with urine injury biomarkers relative to SCr. Conversely, patients with both CysC-AKI and SCr-AKI had the highest biomarker concentrations of the whole group, confirming some important concordance between both methods. Moreover, particularly for NGAL and IL-18, diagnostic characteristics for these biomarkers were much stronger when defining AKI by SCr and CysC, suggesting that including both these markers of GFR to define AKI adds to specificity of AKI diagnosis. Overall, our findings do not support the use of CysC-AKI to "replace" SCr-AKI; however, in studies aiming for highest AKI diagnosis accuracy, both markers might be used to define AKI outcome together. Future studies should address this question.
Most AKI CysC studies have evaluated CysC for early SCr-AKI diagnosis, similar to how urine AKI biomarkers might be used [40] [41] [42] . These studies, of which only one was performed in children, have been reviewed in a meta- Table 3 Area under the receiver operating characteristic +curve and 85 % specificity (spec) and sensitivity (sens) thresholds for biomarkers to discriminate for presence of a) SCr-AKI, b) CysC-AKI 1 SCr serum creatinine, SCr-AKI acute kidney injury defined by SCr rise, CysC cystatin C, CysC-AKI acute kidney injury defined by CysC rise, SCr+ CysC AKI acute kidney injury defined by both a rise in SCr and CysC, AUC area under the receiver operating characteristic curve, NGAL neutrophil gelatinase-associated lipocalin, IL-18 interleukin-18, KIM-1 kidney injury molecule-1 2 Area under the curve for biomarkers to discriminate for the presence of SCr-AKI (left), CysC-AKI (mid), SCr+CysC AKI (right) 3 Biomarker concentrations which resulted in 85 % specificity to diagnose AKI were chosen; the sensitivity at that concentration is provided 4 Biomarker concentrations which resulted in 85 % sensitivity to diagnose AKI were chosen; the specificity at that concentration is provided analysis [43] . The pooled AUC for SCr-AKI diagnosis using CysC was 0.96, which decreased to 0.86 when one study with strong diagnostic characteristics was eliminated, suggesting that CysC is useful for early SCr-AKI diagnosis. The best CysC concentration cut-offs for SCr-AKI diagnosis in these studies varied greatly, from 0.8 to 2.04 mg/l, due to differences in CysC collection times relative to AKI attainment. Krawczeski et al. evaluated early post-operative CysC for AKI diagnosis in children having cardiac surgery; a concentration of 1.16 mg/l had the best diagnostic performance, similar to our evaluated cut-offs [28] . Contrary to these encouraging studies, Wald et al. found that early postoperative CysC predicted SCr-defined AKI occurrence with AUC of only 0.60-0.68, depending on timing of CysC sampling [42] . Unlike a previous study in adult ICU patients [35] , we found that CysC 50 % rise did not occur more often before a 50 % SCr rise, suggesting that CysC is not an early SCr-AKI biomarker. However, as described in a similar recent PICU There are limitations to this study. This study was from a single center, limiting generalizability. The sample size limited our ability to perform subgroup analyses, as evidenced by our rather wide confidence intervals around AUC estimates, and prevented us from more extensively evaluating added benefit of early PICU serum CysC for AKI prediction, over other factors alone (i.e., NRI, IDI). We only included age and PRISM in the clinical model (decided a priori) and though our point estimate for the NRI was quite high (61 %), it barely attained statistical significance (p=0.05); the IDI was not statistically significant. The relatively low sample size also contributed to a low overall event rate, with most patients attaining mild AKI status. Results may differ in future studies able to evaluate more severe AKI or dialysis requirement as outcomes [45] . An important limitation was that our baseline CysC had to be estimated, which may have led to misclassification of CysC-AKI status, and potentially led to a reduced association of CysC-AKI with biomarkers and outcomes. Until CysC is routinely measured in the hospital setting (if it ever occurs), this limitation will be impossible to address. Future studies using CysC change as an AKI outcome might attempt to obtain blood from prior to PICU admission in order to better estimate baseline CysC and improve accuracy of CysC-AKI outcome diagnosis. The timing of urine biomarker measurements must also be considered when interpreting our Fig. 4 Prediction of SCr-AKI using CysC from 2 to 0 days before SCr-AKI (a-c) and from early PICU admission (d and e). The figures represent receiver operating characteristic curves for CysC concentrations to diagnose SCr-AKI. a The receiver operating characteristic curve for CysC obtained 2 days before AKI diagnosis; b for CysC from 1 day before diagnosis; c for CysC from the day of AKI diagnosis; d for CysC obtained in early PICU admission to predict SCr-AKI development within 48 h; e for CysC obtained in early PICU admission to predict SCr-AKI stage 2 development within 48 h. Within each graph, the area under the curve is shown. To the right of each curve, the sensitivity, specificity, and likelihood ratio for selected CysC concentrations cutoffs are shown in association with each graph. SCR-AKI acute kidney injury defined by rise in serum creatinine from baseline, AUC area under the curve, CI confidence interval, CysC cystatin C, AKI acute kidney injury, Sens sensitivity, Spec specificity, LR+positive likelihood ratio, SCr-AKI 2 acute kidney injury stage 2 results. For example, our sample size (and available urine specimens) was only large enough to evaluate biomarkers for AKI discrimination when evaluated on the day of AKI diagnosis. Biomarkers which rise very early (e.g., 2 days before AKI is apparent by SCr rise) might not be diagnostic of AKI when measured on the day AKI becomes clinically apparent (i.e., they are already decreasing in concentration). In studies of children undergoing cardiac surgery, timing of biomarker concentration rises relative to injury timing are very specific and different for different biomarkers [7] . Similarly, when we evaluated early PICU admission biomarkers to predict future AKI development, we may not have measured the biomarkers at their most optimal timing of rise, relative to clinical AKI development. Future larger studies should be performed to understand timing of rise relative to injury and to clinical AKI development, in different diagnostic subgroups.
In conclusion, CysC can be used for early AKI diagnosis when obtained early in PICU admission. Future studies evaluating CysC as an AKI outcome should determine whether obtaining "true" baseline CysC improves performance over use of estimated baseline CysC.
